As there is evidence that SGK-1 may confer resistance of breast cancer and colon carcinoma cells to chemotherapy [32], [33], and that SGK-1 inhibition may increase the toxic effect of chemotherapeutic drugs on tumor cells [17], we decided to test SGK-1 inhibitor GSK 650394 in comparison to cisplatin alone, and both drugs in combination. Here, SGK1 is linked to colon carcinoma.